New cell therapy targets tough cancers in early trial
NCT ID NCT07396090
First seen Feb 12, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This early study tests a new treatment called CAT-101, made from a patient's own immune cells trained to attack cancer cells with specific KRAS mutations. It is given alone or with another drug (tislelizumab) to people with advanced pancreatic cancer or other solid tumors. The main goals are to see if it is safe and to get an early look at whether it shrinks tumors. Only 13 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.